{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T08:57:37Z","timestamp":1792400257462,"version":"4.4.0"},"reference-count":54,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,19]],"date-time":"2025-06-19T00:00:00Z","timestamp":1750291200000},"content-version":"am","delay-in-days":566,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice &amp; Research Clinical Rheumatology"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1016\/j.berh.2023.101865","type":"journal-article","created":{"date-parts":[[2023,8,24]],"date-time":"2023-08-24T21:34:03Z","timestamp":1692912843000},"page":"101865","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"title":["New and future therapies: Changes in the therapeutic armamentarium for SLE"],"prefix":"10.1016","volume":"37","author":[{"given":"Anca","family":"Askanase","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leila","family":"Khalili","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Mertz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Scherlinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eden","family":"Sebbag","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois","family":"Chasset","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renaud","family":"Felten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Arnaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.berh.2023.101865_bib1","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2018-000261","article-title":"Characterisation of anifrolumab, a fully human anti-interferon receptor antagonist antibody for the treatment of systemic lupus erythematosus","volume":"5","author":"Riggs","year":"2018","journal-title":"Lupus Sci Med"},{"issue":"1","key":"10.1016\/j.berh.2023.101865_bib2","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1038\/nri3581","article-title":"Regulation of type I interferon responses","volume":"14","author":"Ivashkiv","year":"2014","journal-title":"Nat Rev Immunol"},{"issue":"4","key":"10.1016\/j.berh.2023.101865_bib3","doi-asserted-by":"crossref","DOI":"10.1016\/S2665-9913(19)30076-1","article-title":"Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1): a randomised, controlled, phase 3 trial","volume":"1","author":"Furie","year":"2019","journal-title":"The Lancet Rheumatology"},{"issue":"3","key":"10.1016\/j.berh.2023.101865_bib4","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa1912196","article-title":"Trial of anifrolumab in active systemic lupus erythematosus","volume":"382","author":"Morand","year":"2020","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.berh.2023.101865_bib6","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1002\/art.39962","article-title":"Anifrolumab, an anti\u2013interferon-\u03b1 receptor monoclonal antibody, in moderate-to-severe systemic lupus erythematosus","volume":"69","author":"Furie","year":"2017","journal-title":"Arthritis Rheumatol"},{"issue":"4","key":"10.1016\/j.berh.2023.101865_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/S2665-9913(21)00317-9","article-title":"Efficacy of anifrolumab across organ domains in patients with moderate-to-severe systemic lupus erythematosus: a post-hoc analysis of pooled data from the TULIP-1 and TULIP-2 trials","volume":"4","author":"Morand","year":"2022","journal-title":"The Lancet Rheumatology"},{"issue":"12","key":"10.1016\/j.berh.2023.101865_bib9","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1056\/NEJMoa2001180","article-title":"Two-year, randomized, controlled trial of belimumab in lupus nephritis","volume":"383","author":"Furie","year":"2020","journal-title":"N Engl J Med"},{"issue":"9767","key":"10.1016\/j.berh.2023.101865_bib10","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/S0140-6736(10)61354-2","article-title":"Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial","volume":"377","author":"Navarra","year":"2011","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.berh.2023.101865_bib11","doi-asserted-by":"crossref","first-page":"3918","DOI":"10.1002\/art.30613","article-title":"A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus","volume":"63","author":"Furie","year":"2011","journal-title":"Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.berh.2023.101865_bib12","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1177\/0961203312465781","article-title":"Effect of belimumab treatment on renal outcomes: results from the phase 3 belimumab clinical trials in patients with SLE","volume":"22","author":"Dooley","year":"2013","journal-title":"Lupus"},{"issue":"12","key":"10.1016\/j.berh.2023.101865_bib13","doi-asserted-by":"crossref","first-page":"2675","DOI":"10.1111\/j.1600-6143.2011.03763.x","article-title":"The PROMISE study: a phase 2b multicenter study of voclosporin (ISA247) versus tacrolimus in de novo kidney transplantation","volume":"11","author":"Busque","year":"2011","journal-title":"Am J Transplant"},{"issue":"5","key":"10.1016\/j.berh.2023.101865_bib14","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1093\/ndt\/gfab022","article-title":"Voclosporin: a novel calcineurin inhibitor with no impact on mycophenolic acid levels in patients with SLE","volume":"37","author":"van Gelder","year":"2022","journal-title":"Nephrol Dial Transplant"},{"issue":"2","key":"10.1016\/j.berh.2023.101865_bib15","doi-asserted-by":"crossref","first-page":"167","DOI":"10.33549\/physiolres.933332","article-title":"Pathophysiological mechanisms of calcineurin inhibitor-induced nephrotoxicity and arterial hypertension","volume":"66","author":"Ho\u0161kov\u00e1","year":"2017","journal-title":"Physiol Res"},{"issue":"1","key":"10.1016\/j.berh.2023.101865_bib17","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.kint.2018.08.025","article-title":"A randomized, controlled double-blind study comparing the efficacy and safety of dose-ranging voclosporin with placebo in achieving remission in patients with active lupus nephritis","volume":"95","author":"Rovin","year":"2019","journal-title":"Kidney Int"},{"issue":"10289","key":"10.1016\/j.berh.2023.101865_bib18","doi-asserted-by":"crossref","first-page":"2070","DOI":"10.1016\/S0140-6736(21)00578-X","article-title":"Efficacy and safety of voclosporin versus placebo for lupus nephritis (AURORA 1): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial","volume":"397","author":"Rovin","year":"2021","journal-title":"Lancet"},{"issue":"Supplement_3","key":"10.1016\/j.berh.2023.101865_bib20","doi-asserted-by":"crossref","DOI":"10.1093\/ndt\/gfac108.004","article-title":"FC056: early reductions in proteinuria with voclosporin treatment across lupus nephritis biopsy classes: pooled data from the AURA-LV and AURORA 1 trials","volume":"37","author":"Askanase","year":"2022","journal-title":"Nephrol Dial Transplant"},{"issue":"7","key":"10.1016\/j.berh.2023.101865_bib21","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1002\/acr.25007","article-title":"Update on the efficacy and safety profile of voclosporin: an integrated analysis of clinical trials in lupus nephritis","volume":"75","author":"Arriens","year":"2023","journal-title":"Arthritis Care Res"},{"issue":"3","key":"10.1016\/j.berh.2023.101865_bib22","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1136\/annrheumdis-2018-214043","article-title":"Organ damage in patients treated with belimumab versus standard of care: a propensity score-matched comparative analysis","volume":"78","author":"Urowitz","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2023.101865_bib23","series-title":"POS1153 applying the working definition of the disease modification criteria to systemic lupus erythematosus treatments from the published literature","author":"Askanase","year":"2023"},{"issue":"1","key":"10.1016\/j.berh.2023.101865_bib24","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2018-000303","article-title":"10 most important contemporary challenges in the management of SLE","volume":"6","author":"Felten","year":"2019","journal-title":"Lupus Sci Med"},{"issue":"2","key":"10.1016\/j.berh.2023.101865_bib25","doi-asserted-by":"crossref","first-page":"243","DOI":"10.3390\/jcm10020243","article-title":"The main challenges in systemic lupus erythematosus: where do we stand?","volume":"10","author":"Piga","year":"2021","journal-title":"J Clin Med"},{"issue":"7","key":"10.1016\/j.berh.2023.101865_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.drudis.2023.103612","article-title":"Novel therapeutic strategies for autoimmune and inflammatory rheumatic diseases","volume":"28","author":"Felten","year":"2023","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.berh.2023.101865_bib27","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.2147\/DDDT.S170969","article-title":"Spotlight on anifrolumab and its potential for the treatment of moderate-to-severe systemic lupus erythematosus: evidence to date","volume":"13","author":"Felten","year":"2019","journal-title":"Drug Des Dev Ther"},{"issue":"2","key":"10.1016\/j.berh.2023.101865_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbspin.2023.105523","article-title":"New biologics and targeted therapies in systemic lupus: from new molecular targets to new indications. A systematic review","volume":"90","author":"Felten","year":"2023","journal-title":"Joint Bone Spine"},{"issue":"4","key":"10.1016\/j.berh.2023.101865_bib29","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1002\/art.34359","article-title":"Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study","volume":"64","author":"Rovin","year":"2012","journal-title":"Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.berh.2023.101865_bib30","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1002\/art.27233","article-title":"Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II\/III systemic lupus erythematosus evaluation of rituximab trial","volume":"62","author":"Merrill","year":"2010","journal-title":"Arthritis Rheum"},{"issue":"9","key":"10.1016\/j.berh.2023.101865_bib31","doi-asserted-by":"crossref","first-page":"2368","DOI":"10.1002\/art.38037","article-title":"Efficacy and safety of ocrelizumab in active proliferative lupus nephritis: results from a randomized, double-blind, phase III study","volume":"65","author":"Mysler","year":"2013","journal-title":"Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.berh.2023.101865_bib32","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1136\/annrheumdis-2021-220920","article-title":"B-cell depletion with obinutuzumab for the treatment of proliferative lupus nephritis: a randomised, double-blind, placebo-controlled trial","volume":"81","author":"Furie","year":"2022","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"10.1016\/j.berh.2023.101865_bib33","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1056\/NEJMoa2106535","article-title":"Phase 2 trial of iberdomide in systemic lupus erythematosus","volume":"386","author":"Merrill","year":"2022","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.berh.2023.101865_bib34","doi-asserted-by":"crossref","first-page":"5397","DOI":"10.1093\/rheumatology\/keab381","article-title":"Phase 2, randomized, placebo-controlled trial of dapirolizumab pegol in patients with moderate-to-severe active systemic lupus erythematosus","volume":"60","author":"Furie","year":"2021","journal-title":"Rheumatology"},{"issue":"10","key":"10.1016\/j.berh.2023.101865_bib35","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1056\/NEJMoa2118025","article-title":"Trial of anti-BDCA2 antibody Litifilimab for systemic lupus erythematosus","volume":"387","author":"Furie","year":"2022","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.berh.2023.101865_bib36","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1056\/NEJMoa2118024","article-title":"Trial of anti-BDCA2 antibody Litifilimab for cutaneous lupus erythematosus","volume":"387","author":"Werth","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.berh.2023.101865_bib38","article-title":"Efficacy and safety of the Bruton's tyrosine kinase inhibitor evobrutinib in systemic lupus erythematosus: results of a phase II, Randomized, Double-Blind, Placebo-Controlled Dose-Ranging Trial","author":"Dj","year":"2023","journal-title":"ACR open rheumatology [Internet]"},{"issue":"6","key":"10.1016\/j.berh.2023.101865_bib39","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.1093\/rheumatology\/keab685","article-title":"Filgotinib or lanraplenib in moderate to severe cutaneous lupus erythematosus: a phase 2, randomized, double-blind, placebo-controlled study","volume":"61","author":"Werth","year":"2022","journal-title":"Rheumatology"},{"key":"10.1016\/j.berh.2023.101865_bib40","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(22)02546-6","article-title":"Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-II)","author":"Petri","year":"2023","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.berh.2023.101865_bib41","author":"Ef"},{"key":"10.1016\/j.berh.2023.101865_bib42","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2020-001490","article-title":"Phase II, randomised, double-blind, multicentre study evaluating the safety and efficacy of filgotinib and lanraplenib in patients with lupus membranous nephropathy","author":"Baker","year":"2020","journal-title":"RMD open [Internet]"},{"key":"10.1016\/j.berh.2023.101865_bib43","series-title":"OP0139 efficacy and safety of ABBV-599 high dose (Elsubrutinib 60 MG and upadacitinib 30 MG) and upadacitinib monotherapy for the treatment of systemic lupus erythematosus: a phase 2, double-blind, PLACEBO-CONTROLLED trial","author":"Merrill","year":"2023"},{"key":"10.1016\/j.berh.2023.101865_bib44","series-title":"Low-dose interleukin-2 therapy in active systemic lupus erythematosus (LUPIL-2): a multicentre, double-blind, randomised and placebo-controlled phase II trial","author":"Humrich","year":"2022"},{"issue":"1","key":"10.1016\/j.berh.2023.101865_bib45","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1136\/annrheumdis-2019-215396","article-title":"Efficacy and safety of low-dose IL-2 in the treatment of systemic lupus erythematosus: a randomised, double-blind, placebo-controlled trial","volume":"79","author":"He","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2023.101865_bib46","first-page":"1","article-title":"The role of platelets in immune-mediated inflammatory diseases","author":"Scherlinger","year":"2023","journal-title":"Nat Rev Immunol"},{"issue":"12","key":"10.1016\/j.berh.2023.101865_bib47","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.7326\/M21-2078","article-title":"Effectiveness of belimumab after rituximab in systemic lupus erythematosus : a randomized controlled trial","volume":"174","author":"Shipa","year":"2021","journal-title":"Ann Intern Med"},{"issue":"3","key":"10.1016\/j.berh.2023.101865_bib48","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2018-025687","article-title":"Phase III, multicentre, randomised, double-blind, placebo-controlled, 104-week study of subcutaneous belimumab administered in combination with rituximab in adults with systemic lupus erythematosus (SLE): BLISS-BELIEVE study protocol","volume":"9","author":"Teng","year":"2019","journal-title":"BMJ Open"},{"issue":"6","key":"10.1016\/j.berh.2023.101865_bib49","first-page":"906","article-title":"Development of an ICOSL and BAFF bispecific inhibitor AMG 570 for systemic lupus erythematosus treatment","volume":"37","author":"Zhang","year":"2019","journal-title":"Clin Exp Rheumatol"},{"issue":"5","key":"10.1016\/j.berh.2023.101865_bib50","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0098315","article-title":"Anti-CD22\/CD20 Bispecific antibody with enhanced trogocytosis for treatment of Lupus","volume":"9","author":"Rossi","year":"2014","journal-title":"PLoS One"},{"issue":"21","key":"10.1016\/j.berh.2023.101865_bib51","doi-asserted-by":"crossref","first-page":"3346","DOI":"10.3390\/cells11213346","article-title":"Blood ADWP (ADWP) of the ES for, et al. Cellular-Based Therapies in Systemic Sclerosis: from Hematopoietic Stem Cell Transplant to Innovative Approaches","volume":"11","author":"Xue","year":"2022","journal-title":"Cells"},{"issue":"8","key":"10.1016\/j.berh.2023.101865_bib52","doi-asserted-by":"crossref","first-page":"3317","DOI":"10.1093\/rheumatology\/keab877","article-title":"Long-term follow-up after lymphodepleting autologous haematopoietic cell transplantation for treatment-resistant systemic lupus erythematosus","volume":"61","author":"Goklemez","year":"2022","journal-title":"Rheumatology (Oxford)"},{"issue":"12","key":"10.1016\/j.berh.2023.101865_bib53","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1136\/ard.2010.148049","article-title":"Current state and future directions of autologous hematopoietic stem cell transplantation in systemic lupus erythematosus","volume":"70","author":"Illei","year":"2011","journal-title":"Ann Rheum Dis"},{"issue":"6295","key":"10.1016\/j.berh.2023.101865_bib54","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1126\/science.aaf6756","article-title":"Reengineering chimeric antigen receptor T cells for targeted therapy of autoimmune disease","volume":"353","author":"Ellebrecht","year":"2016","journal-title":"Science"},{"issue":"6","key":"10.1016\/j.berh.2023.101865_bib55","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1056\/NEJMc2107725","article-title":"CD19-Targeted CAR T cells in refractory systemic lupus erythematosus","volume":"385","author":"Mougiakakos","year":"2021","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.berh.2023.101865_bib56","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1136\/annrheumdis-2019-216379","article-title":"IFN-\u03b1 kinoid in systemic lupus erythematosus: results from a phase IIb, randomised, placebo-controlled study","volume":"79","author":"Houssiau","year":"2020","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"10.1016\/j.berh.2023.101865_bib57","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1007\/s10753-018-0815-6","article-title":"RNAi silencing of HIF-1\u03b1 ameliorates lupus development in MRL\/lpr mice","volume":"41","author":"Zhao","year":"2018","journal-title":"Inflammation"},{"key":"10.1016\/j.berh.2023.101865_bib58","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/j.omtn.2021.03.019","article-title":"The gene silencing of IRF5 and BLYSS effectively modulates the outcome of experimental lupus nephritis","volume":"24","author":"Guiteras","year":"2021","journal-title":"Mol Ther Nucleic Acids"},{"issue":"Suppl5","key":"10.1016\/j.berh.2023.101865_bib59","article-title":"Long-term outcomes in systemic lupus erythematosus: trends over time and major contributors","volume":"59","author":"Arnaud","year":"2020","journal-title":"Rheumatology"}],"container-title":["Best Practice &amp; Research Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521694223000517?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521694223000517?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,19]],"date-time":"2024-06-19T19:52:21Z","timestamp":1718826741000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521694223000517"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":54,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["S1521694223000517"],"URL":"https:\/\/doi.org\/10.1016\/j.berh.2023.101865","relation":{},"ISSN":["1521-6942"],"issn-type":[{"value":"1521-6942","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"New and future therapies: Changes in the therapeutic armamentarium for SLE","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Rheumatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.berh.2023.101865","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"101865"}}